{"groups":[{"description":"Carfilzomib was administered intravenously on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression or end of study. A dose of 20 mg/m\\^2 was administered on day 1 of cycle 1; all subsequent doses were 56 mg/m\\^2. From cycle 13, the frequency of carfilzomib administration was reduced to days 1 and 15 (± 2 days) per cycle until progression or end of study.\n\nDexamethasone was administered orally or intravenously at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle during cycles 1 to 12, and at a dose of 20 mg on days 1 and 15 from cycle 13 until progression or end of study.\n\nPomalidomide 4 mg was administered orally on days 1 to 21 of each cycle until progression or end of study.","id":"FG000","title":"Carfilzomib With Pomalidomide and Dexamethasone (KPd)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Did not receive study treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"54"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Pre-assignment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"37"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Sponsor decision"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"Received Carfilzomib"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"Received Pomalidomide"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"Received Dexamethasone"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"}],"preAssignmentDetails":"Participants with relapsed multiple myeloma whose disease was refractory to lenalidomide were enrolled.","recruitmentDetails":"Participants were enrolled at 25 study centers in Denmark, France, Germany, Greece, Italy, Spain, and the United States from 06 August 2020 to 01 October 2024."}